Berger Montague PC Investigating Claims on Behalf of...
Investigation Deadline:
September 21, 2026
featured news
May 1, 2014
General
Eighth Circuit Confirms $8 Million Whistleblower Reward
In a price-fixing case originating in 2004, two whistleblowers have finally reaped their reward under the False Claims Act and its qui tam provisions. In Rille, ex rel. United States v. PricewaterhouseCoopers, LLC, et al., two relators successfully defeated the DOJ’s motion to preclude recovery of the whistleblower reward citing […]
April 30, 2014
General
Louisiana-Based Home Healthcare Company Amedisys to Pay $150 Million to Settle False Claims Act Allegations
Amedisys, Inc. and its affiliates have agreed to pay $150 million to the federal government in order to settle allegations of fraud and misconduct. According to statements revealed earlier this month, the Department of Justice settled with the home healthcare and hospice provider after uncovering several years’ worth of improper […]
April 29, 2014
General
Office of Inspector General Offers Suggestions to the DOJ to Combat Mortgage Fraud
In yesterday’s post, we began examining a recent audit of the Department of Justice with regard to its mortgage fraud division. Specifically, the Office of Inspector general reviewed several reports offered by the DOJ since the 2008 housing bubble burst and questioned the Department’s record-keeping and prioritization of this devastating […]
April 28, 2014
General
Office of Inspector General Reveals Several Weak Areas of DOJ’s Response to Mortgage Fraud
We regularly report on the effects of mortgage fraud, including several high-profile cases between the Office of Housing and Urban Development (HUD) and several large banking institutions. Mortgage fraud can occur in any number of ways, including false assertions by lenders that borrowers should qualify for mortgage insurance or failing […]
April 25, 2014
General
Pfizer Unsuccessful in Avoiding Off-Label Marketing False Claims Act Case
In a recent False Claims Act case involving the mental health drug Geodon, Pfizer reportedly lost its bid to have the case dismissed after unsuccessfully arguing, among other claims, that relators failed the “first-to-file” and “public disclosure” requirements contained within the language of the FCA. Specifically, the FCA precludes whistleblowers […]featured investigations
$2.4B+
in 2025 post-trial judgments
$55B+
in Settlements & Verdicts
55+
Years of Experience With High-Profile Cases
100+
Attorneys Protecting Your Rights
20+
Years Ranked as Top Law Firm by Chambers USA
50
States in Which The Firm Has Successfully Litigated
